Locally Advanced and Metastatic Pancreatic Cancer: Survival analysis and prognostic factors in a case series
Objective: Systemic treatment of advanced pancreatic adenocarcinoma has resulted in increased survival of patients, but real-life data are scarce, particularly in developing countries. This study aims to analyze the survival of patients with locally advanced, unresectable, or metastatic p...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2020-01-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20200027 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849435114797268992 |
|---|---|
| author | Paloma Porto Amorim Ana Caroline Sobral Patu Camila Sarteschi José Fernando do Prado Moura |
| author_facet | Paloma Porto Amorim Ana Caroline Sobral Patu Camila Sarteschi José Fernando do Prado Moura |
| author_sort | Paloma Porto Amorim |
| collection | DOAJ |
| description |
Objective: Systemic treatment of advanced pancreatic adenocarcinoma has resulted in increased survival of patients, but real-life data are scarce, particularly in developing countries. This study aims to analyze the survival of patients with locally advanced, unresectable, or metastatic pancreatic cancer and factors related to better survival. Methods: an analytical study with a retrospective and prospective part of data from patients with locally advanced or metastatic pancreatic adenocarcinoma treated between January 2012 to December 2018 in the oncology department of the Real Hospital de Beneficência Portuguesa, in Recife (Brazil). Results: Thirty-five patients were assessed. The median age was 68 years old (71.4% = 65 years old), the majority was male (65.7%), with Eastern Cooperative Oncology Group (ECOG) 0 and 1 (65.7%) and metastatic disease (68.6%). The median overall survival was 13.93 months and was longer for patients with ECOG 0 or 1 (20.4 months; p=0.021), Neutrophil-lymphocyte ratio (NLR) <4 (15.63 months; p=0.029) and who received local therapy (23.68 months; p=0.006). Conclusion: An overall median survival, similar to that of other clinical studies, was observed. Such survival was even better in patients with a good clinical condition (ECOG 0 or 1), low NLR, and who received some local therapy. |
| format | Article |
| id | doaj-art-5c8d500d0a7047cab28c4d58040162ce |
| institution | Kabale University |
| issn | 2526-8732 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Thieme Revinter Publicações Ltda. |
| record_format | Article |
| series | Brazilian Journal of Oncology |
| spelling | doaj-art-5c8d500d0a7047cab28c4d58040162ce2025-08-20T03:26:25ZengThieme Revinter Publicações Ltda.Brazilian Journal of Oncology2526-87322020-01-011610.5935/2526-8732.20200027Locally Advanced and Metastatic Pancreatic Cancer: Survival analysis and prognostic factors in a case seriesPaloma Porto Amorim0Ana Caroline Sobral Patu1Camila Sarteschi2José Fernando do Prado Moura3https://orcid.org/0000-0002-6844-2548Real Hospital Português de Beneficência em Pernambuco, Real Instituto de Oncologia - Recife - Pernambuco - BrazilReal Hospital Português de Beneficência em Pernambuco, Real Instituto de Oncologia - Recife - Pernambuco - BrazilReal Hospital Português de Beneficência em Pernambuco, Real Instituto de Oncologia - Recife - Pernambuco - BrazilReal Hospital Português de Beneficência em Pernambuco, Real Instituto de Oncologia - Recife - Pernambuco - Brazil Objective: Systemic treatment of advanced pancreatic adenocarcinoma has resulted in increased survival of patients, but real-life data are scarce, particularly in developing countries. This study aims to analyze the survival of patients with locally advanced, unresectable, or metastatic pancreatic cancer and factors related to better survival. Methods: an analytical study with a retrospective and prospective part of data from patients with locally advanced or metastatic pancreatic adenocarcinoma treated between January 2012 to December 2018 in the oncology department of the Real Hospital de Beneficência Portuguesa, in Recife (Brazil). Results: Thirty-five patients were assessed. The median age was 68 years old (71.4% = 65 years old), the majority was male (65.7%), with Eastern Cooperative Oncology Group (ECOG) 0 and 1 (65.7%) and metastatic disease (68.6%). The median overall survival was 13.93 months and was longer for patients with ECOG 0 or 1 (20.4 months; p=0.021), Neutrophil-lymphocyte ratio (NLR) <4 (15.63 months; p=0.029) and who received local therapy (23.68 months; p=0.006). Conclusion: An overall median survival, similar to that of other clinical studies, was observed. Such survival was even better in patients with a good clinical condition (ECOG 0 or 1), low NLR, and who received some local therapy.http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20200027Survival AnalysisPrognosisAntineoplastic Combined Chemotherapy ProtocolsPancreatic NeoplasmsAdenocarcinomaAnálise de sobrevivênciaPrognósticoAntineoplastic Combined Chemotherapy ProtocolsNeoplasias pancreáticasAdenocarcinoma |
| spellingShingle | Paloma Porto Amorim Ana Caroline Sobral Patu Camila Sarteschi José Fernando do Prado Moura Locally Advanced and Metastatic Pancreatic Cancer: Survival analysis and prognostic factors in a case series Brazilian Journal of Oncology Survival Analysis Prognosis Antineoplastic Combined Chemotherapy Protocols Pancreatic Neoplasms Adenocarcinoma Análise de sobrevivência Prognóstico Antineoplastic Combined Chemotherapy Protocols Neoplasias pancreáticas Adenocarcinoma |
| title | Locally Advanced and Metastatic Pancreatic Cancer: Survival analysis and prognostic factors in a case series |
| title_full | Locally Advanced and Metastatic Pancreatic Cancer: Survival analysis and prognostic factors in a case series |
| title_fullStr | Locally Advanced and Metastatic Pancreatic Cancer: Survival analysis and prognostic factors in a case series |
| title_full_unstemmed | Locally Advanced and Metastatic Pancreatic Cancer: Survival analysis and prognostic factors in a case series |
| title_short | Locally Advanced and Metastatic Pancreatic Cancer: Survival analysis and prognostic factors in a case series |
| title_sort | locally advanced and metastatic pancreatic cancer survival analysis and prognostic factors in a case series |
| topic | Survival Analysis Prognosis Antineoplastic Combined Chemotherapy Protocols Pancreatic Neoplasms Adenocarcinoma Análise de sobrevivência Prognóstico Antineoplastic Combined Chemotherapy Protocols Neoplasias pancreáticas Adenocarcinoma |
| url | http://www.thieme-connect.de/DOI/DOI?10.5935/2526-8732.20200027 |
| work_keys_str_mv | AT palomaportoamorim locallyadvancedandmetastaticpancreaticcancersurvivalanalysisandprognosticfactorsinacaseseries AT anacarolinesobralpatu locallyadvancedandmetastaticpancreaticcancersurvivalanalysisandprognosticfactorsinacaseseries AT camilasarteschi locallyadvancedandmetastaticpancreaticcancersurvivalanalysisandprognosticfactorsinacaseseries AT josefernandodopradomoura locallyadvancedandmetastaticpancreaticcancersurvivalanalysisandprognosticfactorsinacaseseries |